Kristen Riemenschneider, Jeff Jay, Tanny Kang, Max Sanders
January 24, 2026
Freshfields Advises Moderna on Its Ten-Year Agreement With Monash University and the State of Victoria to Produce mRNA Vaccines

1 min
AI-made summary
- Freshfields is advising Moderna on a ten-year agreement with the State of Victoria to build a domestic mRNA vaccine manufacturing facility at Monash University
- The facility aims to produce up to 100 million mRNA respiratory vaccine doses annually, with construction expected to start before the end of 2022 and operations targeted for the end of 2024, pending approvals
- The project will provide Australia with locally manufactured mRNA vaccines for various respiratory viruses.
Freshfields is advising Moderna on its ten-year agreement with the State of Victoria to establish a state-of-the-art, domestic mRNA vaccine manufacturing facility at Monash University, where it will produce up to 100 million mRNA respiratory vaccine doses annually. Construction is expected to commence before the end of 2022, with a target date of the end of 2024 for the facility to become operational, subject to planning and regulatory approvals. The facility, when constructed, is expected to provide people in Australia with access to a domestically manufactured portfolio of mRNA vaccines against respiratory viruses, including COVID-19, seasonal influenza, respiratory syncytial virus (RSV) and other potential respiratory viruses, pending licensure. The Freshfields team was led by life sciences transactions Partner Kristen Riemenschneider, Senior Associate Jeff Jay and Associates Tanny Kang and Max Sanders. ENDS
Article Author
Kristen Riemenschneider, Jeff Jay, Tanny Kang, Max Sanders
The Sponsor
